Opinion

Video

Exploring SGLT2 Inhibitor Benefits in Chronic Kidney Disease

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, and Natalie Bellini, DNP, FNP:-BC, interview Dr Robert Busch, to explore the advantages of SGLT2 inhibitors in chronic kidney disease, cardiovascular health, and their potential to improve overall patient outcomes.

1:21 Treatment landscape for CKD

3:42 Prevalence of CKD in people with diabetes

5:25 Mechanism of SGLT2 inhibitors

8:05 Benefits of SGLT2 inhibitors in non-diabetic patients

9:02 Cardiovascular benefits of SGLT2 inhibitors

11:24 Comparative efficacy of SGLT1,2 inhibitors

13:54 Impact of SGLT2 inhibitors on diabetes

16:50 Adverse effects of SGLT2 inhibitors

20:30 Effect of SGLT2 inhibitors in euglycemic DKA

23:08 Combining SGLT2 inhibitors with other diabetes medications

28:14 Combining finerenone with SGLT2 inhibitors

Related Videos
Yehuda Handelsman, MD: Insulin Resistance in Cardiometabolic Disease and DCRM 2.0 | Image Credit: TMIOA
Matthew Weir, MD: Prioritizing Cardiovascular Risk in Chronic Kidney Disease | Image Credit: University of Maryland
Marianna Fontana, MD, PhD: Declines in Kidney Function Frequent in ATTR-CM  | Image Credit: Radcliffe Cardiology
HCPLive CKD and CVD NewsNetwork Thumbnail
HCPLive CKD and CVD NewsNetwork Thumbnail
HCPLive CKD and CVD NewsNetwork Thumbnail
HCPLive CKD and CVD NewsNetwork Thumbnail
HCPLive CKD and CVD NewsNetwork Thumbnail
Looking Deeper into Genetic Variants of FSGS, with Jennifer Lai Yee, MD, PhD, MPH
Abdul Abdellatif, MD: More Gout Education Needed for Nephrologists
© 2024 MJH Life Sciences

All rights reserved.